Conclusions
suicidality, depression
This open-label randomized clinical trial supports the use of testosterone therapy to significantly reduce gender dysphoria, depression, and suicidality in transgender and gender-diverse adults desiring commencement of testosterone therapy. These findings have critical implications for service access and delivery to ensure timely access to gender-affirming hormone therapy.